AbbVie acquires Celsius Therapeutics for $250M, adding IBD drug CEL383 to its pipeline.
Pharmaceutical giant AbbVie has acquired Celsius Therapeutics for $250 million, specializing in developing an experimental drug for inflammatory bowel disease. The deal adds Celsius' lead asset, CEL383, a potential first-in-class anti-TREM1 antibody for treating IBD, to AbbVie's pipeline. CEL383 completed a phase 1 clinical trial, and the acquisition highlights AbbVie's focus on advancing standard-of-care treatments.
June 27, 2024
6 Articles